Na Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na Li has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Yong Zeng
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University
5 shared publications - Tianyi Wang
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, China
4 shared publications Ruixiang Feng
Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Capital Medical University, Beijing, China
2 shared publicationsWenzhi Du
Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Organ Transplantation and Nephrosis, Shandong Institute of Nephrology, Jinan, Shandong, China
2 shared publicationsDazheng Li
Department of Urology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong Province, China
1 shared publicationHao Li
Department of ICU, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48919
Unveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis
Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.
- 22 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (21) , e48919
Open AccessUnveiling novel drug targets for atherosclerosis: A Mendelian randomization analysis
Atherosclerosis is a leading cause of cardiovascular diseases, necessitating the identification of novel therapeutic targets. By utilizing Mendelian randomization, the aim is to identify potential drug targets for the treatment of atherosclerosis. Using results from genomewide association studies and protein quantitative trait loci data, we genetically identified causal effects of levels of several circulating proteins on atherosclerosis risk, validated using multiple statistical approaches, and identified promising drug targets. These findings demonstrated promising targets worthy of further clinical study, especially lipoprotein (a) and proprotein convertase subtilisin/kexin type 9.
- Open Access
- 26 September 2025
- Published by Springer Nature in Hereditas
- Vol. 162 (1) , 1-13
Analysis of spermidine’s effect on coronary heart disease risk using bidirectional Mendelian randomization and LC-MS/MS
Background: This study examines the causal relationship between spermidine levels and coronary artery disease (CHD) risk using a bidirectional Mendelian Randomization (MR) approach. Methods: We employed genetic variants as instrumental variables to assess the influence of genetically predicted spermidine levels on CHD risk and vice versa. Data for the MR analysis were sourced from the UK Biobank and genome-wide association study datasets, focusing on single nucleotide polymorphisms (SNPs) associated with spermidine levels and CHD. The study also utilized liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate quantification of spermidine in plasma samples. Results: Our analysis identified a significant association between lower genetically predicted spermidine levels and increased CHD risk. The LC-MS/MS results supported the accurate measurement of spermidine, highlighting its feasibility as a clinical biomarker. Conclusions: The findings suggest that reduced spermidine levels may be a significant risk factor for CHD. This study supports the potential of spermidine as a biomarker for CHD risk assessment and its development as a therapeutic target. The integration of genetic and biochemical methodologies enhances our understanding of the role of spermidine in cardiovascular health and its utility in managing CHD risk.
- 26 September 2025
- Published by Springer Nature in Hereditas
- Vol. 162 (1) , 1-13
Open AccessAnalysis of spermidine’s effect on coronary heart disease risk using bidirectional Mendelian randomization and LC-MS/MS
Background: This study examines the causal relationship between spermidine levels and coronary artery disease (CHD) risk using a bidirectional Mendelian Randomization (MR) approach. Methods: We employed genetic variants as instrumental variables to assess the influence of genetically predicted spermidine levels on CHD risk and vice versa. Data for the MR analysis were sourced from the UK Biobank and genome-wide association study datasets, focusing on single nucleotide polymorphisms (SNPs) associated with spermidine levels and CHD. The study also utilized liquid chromatography-tandem mass spectrometry (LC-MS/MS) for accurate quantification of spermidine in plasma samples. Results: Our analysis identified a significant association between lower genetically predicted spermidine levels and increased CHD risk. The LC-MS/MS results supported the accurate measurement of spermidine, highlighting its feasibility as a clinical biomarker. Conclusions: The findings suggest that reduced spermidine levels may be a significant risk factor for CHD. This study supports the potential of spermidine as a biomarker for CHD risk assessment and its development as a therapeutic target. The integration of genetic and biochemical methodologies enhances our understanding of the role of spermidine in cardiovascular health and its utility in managing CHD risk.
- Open Access
- 17 September 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 498, 139897
Integrated analysis of microplastics in human gallbladder and bile using multimodal detection techniques
- 17 September 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 498, 139897
Open AccessIntegrated analysis of microplastics in human gallbladder and bile using multimodal detection techniques
- Open Access
- 1 September 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 497, 139728
Microplastic contamination in kidney transplant donor tissues and its association with early post-transplant blood pressure changes in recipients: A multi-modal analytical study
- 1 September 2025
- Published by Elsevier in Journal of Hazardous Materials
- Vol. 497, 139728
Open AccessMicroplastic contamination in kidney transplant donor tissues and its association with early post-transplant blood pressure changes in recipients: A multi-modal analytical study